Market Update: Eli Lilly & Company (NYSE:LLY) – CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union
June 27, 2014 at 08:01 AM EDT
[PR Newswire] – INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ — The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly to Participate in Bernstein Strategic Decisions Conference Market Update (NYSE:LLY): Lilly Declares Second-Quarter 2014 Dividend Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Reports First-Quarter 2014 Results